News
Hosted on MSN1mon
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are CrucialIncretin analogs include injectable GLP-1s, oral GLP-1s, and GLP-1/GIP dual agonists. Lilly has been steadily gaining market share on Novo Nordisk since May 2024.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback